Adaxio is commonly used to help manage symptomatic relief across key therapeutic domains.

Symptom Domains and Use Categories

This medication is applied across conditions presenting with acute episodes of localized fungal and yeast infections. It is relevant in contexts marked by increased discomfort or tension due to common dermatophyte infections—such as Tinea pedis (athlete's foot), Tinea cruris (jock itch), and Tinea corporis (ringworm)—as well as cutaneous and vulvovaginal candidiasis (thrush).

Adaxio is applied in scenarios where additional management of discomfort is required for symptoms related to inflammatory or irritative states, including intense itching, redness, soreness, and burning. The application contributes to improved day-to-day comfort during symptomatic periods by supporting patients during episodes of heightened discomfort.

It is also considered relevant for supportive care when conditions involving inflammatory or irritative processes, like diaper dermatitis, are complicated by secondary fungal overgrowth in children.

“Adaxio helps address symptom clusters that may become intense or disruptive, offering symptomatic relief to help patients cope more steadily.”

---

Quick Fact Block

Quick Fact: Relief for Key Symptoms	Description
Primary Symptoms	Itching, burning, redness, scaling, soreness.
Target Conditions	Tinea pedis, Tinea cruris, Ringworm, Vulvovaginal candidiasis.
Core Benefit	Contributes to easing the overall symptom load during management.

Who can and cannot use Adaxio (ANTIFUNGAL)?

Adaxio Shampoo is a veterinary medicinal product intended exclusively for dogs. The regulatory documentation strictly defines specific populations for whom use is prohibited, restricted, or requires special professional consideration.

Eligibility and Restrictions

Classification	Population/Condition	Eligibility Status (Regulatory Basis)
Contraindicated	Animals with hypersensitivity to the active substances (chlorhexidine, miconazole) or any excipients.	Prohibited (Formal Contraindication)
Use Restricted	Pregnant or lactating females.	Use Not Established/Requires Benefit-Risk Assessment by a veterinarian.
Age Restriction	Puppies (in relation to nursing females).	Use Limited (Must not contact nursing females until the treated coat is dry).

Use of the product is formally contraindicated if the animal has a known hypersensitivity to the ingredients, as specified in the official labeling. For use during pregnancy and lactation, the safety of the product has not been definitively established; therefore, administration is permitted only according to a formal benefit/risk assessment carried out by the responsible veterinarian. Additionally, contact between puppies and nursing females must be prevented until the treated animal's coat is completely dry.

Interactions with other medicines and products

Official regulatory information for Miconazole Nitrate describes potential systemic drug interactions despite the minimal absorption from topical and intravaginal application.

Classification	Interacting Agents	Official Statement / Constraint
Clinically Significant	Warfarin and other oral anticoagulants (e.g., Dicumarol)	Miconazole is a documented inhibitor of CYP2C9 and CYP3A4, which can enhance the anticoagulant effect and lead to an increased International Normalized Ratio (INR) and heightened risk of bleeding.
Systemic Risk	Oral Hypoglycemics (e.g., Sulfonylureas like Glibenclamide, Gliclazide)	Potential for increased plasma concentrations of these drugs, which may enhance their effects and side effects.
Systemic Risk	Phenytoin	Potential for increased plasma concentrations, which may increase the risk of toxicity.
Procedural Restriction	Latex or Rubber Products (e.g., diaphragms, condoms)	Concurrent use of the intravaginal cream or suppositories is not recommended due to documented incompatibility of the product base with these materials.

Regulatory documents emphasize that the systemic interaction potential exists, requiring caution when Adaxio is used concurrently with the listed medicinal products that are substrates for CYP2C9 or CYP3A4. This mandates close patient monitoring for signs of enhanced drug effects. The interaction profile is defined by both this systemic metabolic risk and the local restriction concerning latex products.

Adaxio is an antifungal agent whose action centers on disrupting the integrity of the fungal cell membrane . This disruption is achieved by interfering with the synthesis of ergosterol, an essential sterol component unique to fungal membranes.

The molecular action involves the inhibition of the enzyme lanosterol 14alpha-demethylase (CYP51). This enzyme catalyzes a critical step in the ergosterol biosynthesis pathway, converting lanosterol into intermediate compounds. By binding to and inhibiting CYP51, Adaxio blocks the necessary demethylation reaction. This blockage leads to two primary intracellular consequences: the depletion of functional ergosterol and the toxic accumulation of methylated sterols, such as 14alpha-methylated sterols, within the cell.

The resulting changes to the cell membrane's lipid composition—specifically, the scarcity of ergosterol and the buildup of unusable sterols—compromises its structural and functional characteristics. This alters the membrane's permeability, inhibits membrane-bound enzyme activity, and ultimately prevents the fungal cell from maintaining its necessary internal environment and completing key cellular processes.

How to Use Adaxio (Miconazole Nitrate)

The official instructions for using Miconazole Nitrate are strictly defined by its pharmaceutical form and the approved administration route to ensure localized treatment of fungal infections. The medicine is primarily administered via topical (skin application), intravaginal (using suppositories or cream), or buccal routes (using the 50 mg tablet form).

Standard Dosing Regimens and Frequency

Indication Type	Administration Route & Frequency	Treatment Duration Pattern
Tinea/Cutaneous Candidiasis	Topical (Cream/Powder/Spray) twice daily (morning and evening)	2 to 4 consecutive weeks
Vulvovaginal Candidiasis	Intravaginal (Suppositories/Cream) once daily at bedtime	1, 3, or 7 consecutive days

For topical use, a thin layer of the formulation is applied to the affected area and surrounding skin. Intravaginal treatments are structured into fixed courses, where higher strength suppositories (1200 mg) define a one-day course, and lower strengths (100 mg) define a seven-day course. For oropharyngeal candidiasis, a 50 mg buccal tablet is applied to the upper gum once daily for 14 consecutive days.

Administration Conditions

Before topical application, the affected area must be cleaned and thoroughly dried. Intravaginal formulations are typically administered at bedtime to maximize drug retention. For the buccal tablet, the user is instructed not to crush, chew, or swallow the tablet. Usage is generally designated for adults and adolescents 12 years of age and older for vaginal application and 2 years of age and older for most topical skin infections.

Research Evidence / Overview of Studies for Adaxio (Miconazole Nitrate)

---

Evidence for Vulvovaginal and Cutaneous Candidiasis Studies

Miconazole Nitrate has been evaluated in research that includes Randomized Controlled Trials (RCTs) for localized yeast infections. These short-term studies were studied for infections of the skin (cutaneous) and internal thrush (vulvovaginal candidiasis). These trials typically compared Miconazole Nitrate against a placebo or against other common active antifungal treatments. Researchers examined two primary outcomes: Clinical Cure, which involved tracking the resolution of symptoms like itching and discharge; and Mycological Cure, which monitored the laboratory clearance of the Candida species. Follow-up durations were limited, meaning data for long-term outcomes and the prevention of recurrence remain limited.

---

Evidence for Studies on Dermatophyte Infections (Tinea)

Research has explored the evaluation of Miconazole Nitrate formulations for conditions such as Tinea pedis (athlete's foot) and Tinea cruris (jock itch). The evidence stems from comparative clinical trials where Miconazole was evaluated against other azoles. Studies monitored the visual appearance of the skin (clinical outcome) and the laboratory status (mycological outcome). Findings describe patterns observed in the studies related to mycological clearance metrics which were also measured in trials comparing Miconazole Nitrate to other topical agents. Comparative evidence is lacking when measuring against some of the newest classes of antifungal agents available today.

---

Gaps in Knowledge and Unresolved Scientific Questions

Research highlights what is known—and what is still uncertain—about Miconazole Nitrate formulations. The main uncertainties relate to long-term outcomes, as follow-up durations were limited in key trials, meaning data on the long-term impact on recurrence rates remain insufficient. Research also describes patterns related to resistance monitoring, particularly where formulations may lead to higher systemic absorption, noting that this is an area where data are still emerging and certainty remains low. Findings describe group patterns, not personal outcomes, and evidence quality varies across studies, leaving some subgroup findings uncertain.

Key Studies & References

1. Label: MICONAZOLE NITRATE cream - DailyMed (OTC Tinea labeling)
2. Efficacy of topical antifungal drugs in different dermatomycoses: a systematic review with meta-analysis (includes miconazole for cutaneous candidiasis)

Common questions about Adaxio (ANTIFUNGAL) (FAQ)

---

Q: Is Adaxio a prescription medicine or can I buy it over the counter?

The active ingredient in Adaxio, Miconazole Nitrate, is commonly found in formulations classified in regulatory documents as Over-the-Counter (OTC) drugs for typical topical and vaginal uses. This classification indicates that many forms of the medicine are available without requiring a prescription.

Q: Is Adaxio safe to use for children?

Regulatory labeling indicates that some topical forms are not for use in children under 2 years of age unless specified by a healthcare provider. Use in older children and adolescents may vary, and consultation is generally advised based on the specific formulation and intended use.

Q: Are there any specific foods or drinks I need to avoid while on Adaxio?

For the topical cream and vaginal forms, official product information does not describe specific restrictions related to food or alcohol consumption. It is noted that the oral (buccal) formulation does carry a precaution regarding individuals with a known hypersensitivity to milk protein concentrate.

Q: Is Adaxio safe to use during pregnancy?

Official regulatory documents indicate that the effectiveness of Adaxio during pregnancy has not been definitively established. For products with even minimal absorption, official information indicates that use of the vaginal forms is generally restricted in the first trimester unless deemed essential by a healthcare professional.

Q: Is it normal to feel a mild burning sensation when applying Adaxio?

Regulatory reports for the vaginal forms indicate that a temporary increase in sensations like burning, itching, or irritation may occur when the medicine is first applied. For topical products, official labels describe the need to discontinue use and seek guidance if significant irritation or discomfort develops.

Q: What should be done if too much Adaxio is used?

Official product warnings emphasize that if the medicine, which is generally for external use, is accidentally swallowed, immediate contact with a Poison Control Center or a healthcare professional is described as necessary. The risk profile differs greatly if the product is ingested.

Q: Does Adaxio treat internal or external fungal infections?

Adaxio is primarily classified as a topical or mucocutaneous treatment. Regulatory labels state that the cream and powder forms are for external use only on the skin, and other forms are designed for vaginal use.

Q: Is Adaxio the same as [common competitor antifungal name]?

Adaxio's active ingredient is Miconazole Nitrate. While Miconazole belongs to the same azole class, studies have documented differences between agents, such as in the required treatment duration or available strengths/forms, when comparing Miconazole to other azole medications.

Q: Can Adaxio affect my ability to drive or operate machinery?

Regulatory safety documents for the topical cream formulation include statements indicating that it has no known influence on a person’s ability to drive or operate machinery.

Q: Why do people sometimes confuse Adaxio with medicines for yeast infections?

The confusion stems from the medicine's primary use. The active ingredient, Miconazole Nitrate, is commonly used in formulations specifically marketed and officially labeled to treat vaginal yeast infections, also known as vulvovaginal candidiasis.

Q: How is Adaxio's purpose different from topical antifungal creams?

Adaxio's active ingredient, Miconazole, is classified as a synthetic imidazole derivative within the azole antifungal class. It is described as having broad-spectrum activity, targeting various types of fungi, including dermatophytes and Candida species.

Q: What are the signs that Adaxio is not working for my infection?

Official labels state that if there is no improvement within specific timeframes (which vary by infection type), a healthcare professional should be consulted. These timeframes range from 3 to 7 days for vaginal infections up to 2 to 4 weeks for certain topical skin infections.

Q: What does the term 'systemic exposure' mean regarding Adaxio?

In regulatory summaries, the term refers to the amount of medicine that enters the systemic circulation, or the main bloodstream. Official information describes the medicine as having minimal absorption into the body after topical or vaginal application.

Q: Why is it described that Adaxio can cause stomach upset?

Regulatory information for the oral (buccal) formulation of Miconazole lists common adverse reactions that affect the digestive system. These include reports of nausea, vomiting, and upper abdominal pain.

Q: What are the most commonly reported side effects of Adaxio?

For the vaginal form, common effects reported include a mild, temporary increase in burning, itching, or irritation at the application site. For the oral (buccal) formulation, reactions like headache, nausea, and diarrhea are listed as commonly reported effects.

How to Store and Dispose of Adaxio (ANTIFUNGAL)

The storage and disposal of Adaxio (Miconazole Nitrate) must adhere strictly to official regulatory guidelines to maintain its effectiveness and ensure safety.

---

Storage Requirements

Adaxio must be stored at Controlled Room Temperature, typically between 20°C and 25°C (68°F and 77°F). The product must be protected from freezing and excessive heat.

It is required to keep the medicine in its original container and ensure the container is tightly closed. The container must also be protected from light and moisture.

All medicines must be stored out of the reach of children.

---

Disposal Instructions

Unused or expired Adaxio should be thrown away by following established FDA guidelines and local regulations. To protect the environment, the product must not be disposed of by flushing it down the toilet or pouring it into a drain or waterway.